New Blood Test Detects Breast Cancer Return

Researchers have developed a novel blood test capable of detecting the recurrence of breast cancer. This innovative method analyzes circulating cell-free DNA (cfDNA) fragments and the arrangement of nucleosomes, which are DNA-protein structures, offering a less invasive alternative to current diagnostic tools like mammograms and biopsies. The study, published on June 1, 2026, focused on identifying changes in specific genomic regions and cfDNA fragment lengths. A sophisticated machine-learning model was instrumental in accurately distinguishing between primary and recurrent breast cancer. This breakthrough holds the potential to monitor patients during and after treatment, identifying therapy resistance and enabling earlier, more personalized interventions. Further large-scale studies are planned to validate these findings across different breast cancer subtypes and patient demographics.